3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
X-Rays
8
Specimen Handling
8
Cyclophosphamide
8
Phantoms, Imaging
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
cabozantinib
5
Gemcitabine
5
Biopsy
5
Nuclear Medicine Department, Hospital
4
Methotrexate
4
Doxorubicin
4
fludarabine phosphate
3
Ifosfamide
3
Cisplatin
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
mifamurtide
2
larotrectinib
2
ivosidenib
2
irinotecan sucrosofate
2
ensartinib
2
atezolizumab
2
Vincristine
2
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
durvalumab
×
90 days
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled